Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations

References

• Albrecht, B. K., Harmange, J. C., Bauer, D., Berry, L., Bode, C., Boezio, A. A., … Bellon, S. F. (2008). Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. Journal of Medicinal Chemistry, 51, 2879–2882. doi:10.1021/jm800043g
   PubMed Web of Science ®Google Scholar
• Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003). Met, metastasis, motility and more. Nature Reviews Molecular Cell Biology, 4, 915–925. doi:10.1038/nrm1261
   PubMed Web of Science ®Google Scholar
• Boccaccio, C., & Comoglio, P. M. (2006). Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nature Reviews Cancer, 6, 637–645. doi:10.1038/nrc1912
   PubMed Web of Science ®Google Scholar
• Boezio, A. A., Berry, L., Albrecht, B. K., Bauer, D., Bellon, S. F., Bode, C., … Harmange, J. C. (2009). Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorganic & Medicinal Chemistry Letters, 19, 6307–6312. doi:10.1016/j.bmcl.2009.09.096
   PubMed Web of Science ®Google Scholar
• Chang, H. W., Chung, F. S., & Yang, C. N. (2013). Molecular modeling of p38alpha mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations. Journal of Chemical Information and Modeling, 53, 1775–1786. doi:10.1021/ci4000085
   PubMed Web of Science ®Google Scholar
• Chen, F., Wang, Y., Ai, J., Zhan, Z., Lv, Y., Liang, Z., … Duan, W. (2012). O-linked triazolotriazines: Potent and selective c-Met inhibitors. ChemMedChem, 7, 1276–1285. doi:10.1002/cmdc.201200145
   PubMed Web of Science ®Google Scholar
• Cui, J. J. (2014). Targeting receptor tyrosine kinase MET in cancer: Small molecule inhibitors and clinical progress. Journal of Medicinal Chemistry, 57, 4427–4453. doi:10.1021/jm401427c
   PubMed Web of Science ®Google Scholar
• Cui, J. J., McTigue, M., Nambu, M., Tran-Dube, M., Pairish, M., Shen, H., … Christensen, J. (2012). Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1 -yl)ethanol (PF-04217903) for the treatment of cancer. Journal of Medicinal Chemistry, 55, 8091–8109. doi:10.1021/jm300967g
   PubMed Web of Science ®Google Scholar
• Cui, J. J., Tran-Dube, M., Shen, H., Nambu, M., Kung, P. P., Pairish, M., … Edwards, M. P. (2011). Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Journal of Medicinal Chemistry, 54, 6342–6363. doi:10.1021/jm2007613
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., Pedersen, L. (1993). Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98, 10089–10092. doi:10.1063/1.464397
   Web of Science ®Google Scholar
• Di Renzo, M. F., Narsimhan, R. P., Olivero, M., Bretti, S., Giordano, S., Medico, E., … Comoglio, P. M. (1991). Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene, 6, 1997–2003
   PubMed Web of Science ®Google Scholar
• Ding, K., Zhang, H., Wang, H., Lv, X., Pan, L., Zhang, W., & Zhuang, S. (2015). Atomic-scale investigation of the interactions between tetrabromobisphenol A, tetrabromobisphenol S and bovine trypsin by spectroscopies and molecular dynamics simulations. Journal of Hazardous Materials, 299, 486–494. doi:10.1016/j.jhazmat.2015.07.050
   PubMed Web of Science ®Google Scholar
• Duan, Y., Wu, C., Chowdhury, S., Lee, M. C., Xiong, G., Zhang, W., … Kollman, P. (2003). A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. Journal of Computational Chemistry, 24, 1999–2012. doi:10.1002/jcc.10349
   PubMed Web of Science ®Google Scholar
• Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009). Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clinical Cancer Research, 15, 2207–2214. doi:10.1158/1078-0432.CCR-08-1306
   PubMed Web of Science ®Google Scholar
• Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., … Janne, P. A. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039–1043. doi:10.1126/science.1141478
   PubMed Web of Science ®Google Scholar
• Fang, L., Chow, K. M., Hou, S., Xue, L., Chen, X., Rodgers, D. W., … Zhan, C. G. (2014). Rational design, preparation, and characterization of a therapeutic enzyme mutant with improved stability and function for cocaine detoxification. ACS Chemical Biology, 9, 1764–1772. doi:10.1021/cb500257s
   PubMed Web of Science ®Google Scholar
• Feng, Z., Alqarni, M. H., Yang, P., Tong, Q., Chowdhury, A., Wang, L., & Xie, X. Q. (2014). Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs. Journal of Chemical Information and Modeling, 54, 2483–2499. doi:10.1021/ci5002718
   PubMed Web of Science ®Google Scholar
• Gherardi, E., Birchmeier, W., Birchmeier, C., & Vande Woude, G. (2012). Targeting MET in cancer: Rationale and progress. Nature Reviews Cancer, 12, 89–103. doi:10.1038/nrc3205
   PubMed Web of Science ®Google Scholar
• Giordano, S., Maffe, A., Williams, T. A., Artigiani, S., Gual, P., Bardelli, A., … Comoglio, P. M. (2000). Different point mutations in the met oncogene elicit distinct biological properties. FASEB Journal, 14, 399–406.
   PubMed Web of Science ®Google Scholar
• Huang, Y. Y., Li, Z., Cai, Y. H., Feng, L. J., Wu, Y., Li, X., & Luo, H. B. (2013). The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: A modeling study. Journal of Chemical Information and Modeling, 53, 3044–3053. doi:10.1021/ci400458z
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L. C., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics, 79, 926–935. doi:10.1063/1.445869
   Web of Science ®Google Scholar
• Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., … Cheatham 3rd, T. E. (2000). Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research, 33, 889–897. doi:10.1021/ar000033j
   PubMed Web of Science ®Google Scholar
• Kontoyianni, M., McClellan, L. M., & Sokol, G. S. (2004). Evaluation of docking performance: Comparative data on docking algorithms. Journal of Medicinal Chemistry, 47, 558–565. doi:10.1021/jm0302997
   PubMed Web of Science ®Google Scholar
• Kumar, A., & Purohit, R. (2012). Computational screening and molecular dynamics simulation of disease associated nsSNPs in CENP-E. Mutation Research, 738–739, 28–37. doi:10.1016/j.mrfmmm.2012.08.005
   PubMed Web of Science ®Google Scholar
• Liao, J. J. (2007). Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. Journal of Medicinal Chemistry, 50, 409–424. doi:10.1021/jm0608107
   PubMed Web of Science ®Google Scholar
• Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S., … Salgia, R. (2008). Expression and mutational analysis of MET in human solid cancers. Genes, Chromosomes & Cancer, 47, 1025–1037. doi:10.1002/gcc.20604
   PubMed Web of Science ®Google Scholar
• Mandal, R. S., Panda, S., & Das, S. (2017). In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein. Journal of Biomolecular Structure & Dynamics, 1–15. doi:10.1080/07391102.2017.1305295
   PubMed Web of Science ®Google Scholar
• Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., & Salgia, R. (2002). Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine & Growth Factor Reviews, 13, 41–59. doi:10.1016/S1359-6101(01)00029-6
   PubMed Web of Science ®Google Scholar
• Migliore, C., & Giordano, S. (2008). Molecular cancer therapy: Can our expectation be MET? European Journal of Cancer, 44, 641–651. doi:10.1016/j.ejca.2008.01.022
   PubMed Web of Science ®Google Scholar
• Onufriev, A., Bashford, D., & Case, D. A. (2004). Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins, 55, 383–394. doi:10.1002/prot.20033
   PubMed Web of Science ®Google Scholar
• Palaniappan, C., Rao, S., & Ramalingam, R. (2016). Unraveling the molecular effects of mutation L270P on Wiskkot-Aldrich syndrome protein: Insights from molecular dynamics approach. Journal of Biomolecular Structure & Dynamics, 34, 2011–2022. doi:10.1080/07391102.2015.1104263
   PubMed Web of Science ®Google Scholar
• Peters, S., & Adjei, A. A. (2012). MET: A promising anticancer therapeutic target. Nature Reviews Clinical Oncology, 9, 314–326. doi:10.1038/nrclinonc.2012.71
   PubMed Web of Science ®Google Scholar
• Porter, J. (2010). Small molecule c-Met kinase inhibitors: A review of recent patents. Expert Opinion on Therapeutic Patents, 20, 159–177. doi:10.1517/13543770903514137
   PubMed Web of Science ®Google Scholar
• Rajendran, V. (2016). Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1. Molecular BioSystems, 12, 2276–2287. doi:10.1039/c6mb00182c
   PubMed Web of Science ®Google Scholar
• Rajendran, V., Gopalakrishnan, C., & Purohit, R. (2016). Impact of point mutation P29S in RAC1 on tumorigenesis. Tumour Biology, 37, 15293–15304. doi:10.1007/s13277-016-5329-y
   PubMed Web of Science ®Google Scholar
• Rajendran, V., Purohit, R., & Sethumadhavan, R. (2012). In silico investigation of molecular mechanism of laminopathy caused by a point mutation (R482W) in lamin A/C protein. Amino Acids, 43, 603–615. doi:10.1007/s00726-011-1108-7
   PubMed Web of Science ®Google Scholar
• Roy, K. K., & Saxena, A. K. (2011). Structural basis for the beta-adrenergic receptor subtype selectivity of the representative agonists and antagonists. Journal of Chemical Information and Modeling, 51, 1405–1422. doi:10.1021/ci2000874
   PubMed Web of Science ®Google Scholar
• Ryckaert, J.-P. , Ciccotti G., Berendsen, H. (1977). Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. Journal of Computational Physics, 23, 327–341. doi:10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Ryu, J. W., Han, S. Y., Yun, J. I., Choi, S. U., Jung, H., Ha, J. D., … Lee, J. (2011). Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry Letters, 21, 7185–7188. doi:10.1016/j.bmcl.2011.09.066
   PubMed Web of Science ®Google Scholar
• Sabbah, D. A., Vennerstrom, J. L., & Zhong, H. A. (2012). Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations. Journal of Chemical Information and Modeling, 52, 3213–3224. doi:10.1021/ci3003057
   PubMed Web of Science ®Google Scholar
• Salmas, R. E., Mestanoglu, M., Unlu, A., Yurtsever, M., & Durdagi, S. (2016). Mutated form (G52E) of inactive diphtheria toxin CRM197: Molecular simulations clearly display effect of the mutation to NAD binding. Journal of Biomolecular Structure & Dynamics, 34, 2462–2468. doi:10.1080/07391102.2015.1119060
   PubMed Web of Science ®Google Scholar
• Shen, L., Johnson, T. L., Clugston, S., Huang, H., Butenhof, K. J., & Stanton, R. V. (2011). Molecular dynamics simulation and binding energy calculation for estimation of oligonucleotide duplex thermostability in RNA-based therapeutics. Journal of Chemical Information and Modeling, 51, 1957–1965. doi:10.1021/ci200141j
   PubMed Web of Science ®Google Scholar
• Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., … Golub, T. R. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 487, 500–504. doi:10.1038/nature11183
   PubMed Web of Science ®Google Scholar
• Timofeevski, S. L., McTigue, M. A., Ryan, K., Cui, J., Zou, H. Y., Zhu, J. X., & Murray, B. W. (2009). Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry, 48, 5339–5349. doi:10.1021/bi900438w
   PubMed Web of Science ®Google Scholar
• Turke, A. B., Zejnullahu, K., Wu, Y. L., Song, Y., Dias-Santagata, D., Lifshits, E., & Janne, P. A. (2010). Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell, 17, 77–88. doi:10.1016/j.ccr.2009.11.022
   PubMed Web of Science ®Google Scholar
• Ugolini, A., Kenigsberg, M., Rak, A., Vallee, F., Houtmann, J., Lowinski, M., … Schio, L. (2016). Discovery and pharmacokinetic and pharmacological properties of the potent and selective MET kinase inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazo l-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844). Journal of Medicinal Chemistry, 59, 7066–7074. doi:10.1021/acs.jmedchem.6b00280
   PubMed Web of Science ®Google Scholar
• Underiner, T. L., Herbertz, T., & Miknyoczki, S. J. (2010). Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anti-Cancer Agents in Medicinal Chemistry, 10, 7–27. doi:10.2174/1871520611009010007
   PubMed Web of Science ®Google Scholar
• Wang, J., Wang, W., Kollman, P. A., & Case, D. A. (2006). Automatic atom type and bond type perception in molecular mechanical calculations. Journal of Molecular Graphics and Modelling, 25, 247–260. doi:10.1016/j.jmgm.2005.12.005
   PubMed Web of Science ®Google Scholar
• Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., … Settleman, J. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 487, 505–509. doi:10.1038/nature11249
   PubMed Web of Science ®Google Scholar
• Yanagita, H., Yamamoto, N., Fuji, H., Liu, X., Ogata, M., Yokota, M., … Hoshino, T. (2012). Mechanism of drug resistance of hemagglutinin of influenza virus and potent scaffolds inhibiting its function. ACS Chemical Biology, 7, 552–562. doi:10.1021/cb200332k
   PubMed Web of Science ®Google Scholar
• Yang, Y., Shen, Y., Liu, H., & Yao, X. (2011). Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38alpha MAP kinase. Journal of Chemical Information and Modeling, 51, 3235–3246. doi:10.1021/ci200159g
   PubMed Web of Science ®Google Scholar
• Ye, L., Ou, X., Tian, Y., Yu, B., Luo, Y., Feng, B., … Wu, S. (2013). Indazoles as potential c-Met inhibitors: Design, synthesis and molecular docking studies. European Journal of Medicinal Chemistry, 65, 112–118. doi:10.1016/j.ejmech.2013.04.004
   PubMed Web of Science ®Google Scholar
• Ye, L., Tian, Y., Li, Z., Jin, H., Zhu, Z., Wan, S., … Wu, S. (2012). Design, synthesis and molecular docking studies of some novel spiro[indoline-3,4′-piperidine]-2-ones as potential c-Met inhibitors. European Journal of Medicinal Chemistry, 50, 370–375. doi:10.1016/j.ejmech.2012.02.016
   PubMed Web of Science ®Google Scholar
• Yuan, H. L., Lu, T., Ran, T., Liu, H. C., Lu, S., Tai, W. T., … Chen, Y. D. (2011). Novel strategy for three-dimensional fragment-based lead discovery. Journal of Chemical Information and Modeling, 51, 959–974. doi:10.1021/ci200003c
   PubMed Web of Science ®Google Scholar
• Yuan, H. L., Zhuang, J., Hu, S. H., Li, H. C., Xu, J. X., Hu, Y. N., … Lu, T. (2014). Molecular modeling of exquisitely selective c-Met inhibitors through 3D-QSAR and molecular dynamics simulations. Journal of Chemical Information and Modeling, 54, 2544–2554. doi:10.1021/ci500268s
   PubMed Web of Science ®Google Scholar
• Zhao, F. L., Yang, G. H., Xiang, S., Gao, D. D., & Zeng, C. (2017). In silico analysis of the effect of mutation on epidermal growth factor receptor in non-small-cell lung carcinoma: From mutational analysis to drug designing. Journal of Biomolecular Structure & Dynamics, 35, 427–434. doi:10.1080/07391102.2016.1146165
   PubMed Web of Science ®Google Scholar
• Zhuang, S., Wang, H., Ding, K., Wang, J., Pan, L., Lu, Y., … Zhang, C. (2016). Interactions of benzotriazole UV stabilizers with human serum albumin: Atomic insights revealed by biosensors, spectroscopies and molecular dynamics simulations. Chemosphere, 144, 1050–1059. doi:10.1016/j.chemosphere.2015.09.085
   PubMed Web of Science ®Google Scholar
• Zhuang, S., Zhang, C., & Liu, W. (2014). Atomic insights into distinct hormonal activities of Bisphenol A analogues toward PPARgamma and ERalpha receptors. Chemical Research in Toxicology, 27, 1769–1779. doi:10.1021/tx500232b
   PubMed Web of Science ®Google Scholar